COVID-19 HOPE Program
In April 2020, Atossa launched the COVID-19 HOPE Program to develop a therapy to improve lung function and reduce the amount of time that COVID-19 patients are on ventilators. This program uses a novel combination of two drugs that have been previously approved by the FDA for other diseases.
Transforming the Breast Cancer Paradigm
-
Endoxifen
We are developing the promise of endoxifen and exploiting its potential to both help prevent as well as to treat breast cancer with our proprietary Topical and Oral Endoxifen.
-
Microcatheters
We are developing proprietary intraductal microcatheter technology for the potential delivery of drugs and immunotherapies (such as CAR-T) through the breast ducts directly to the site of the cancer.
Developing Solutions to Address all Sections of the Breast Cancer Paradigm
-
Prevention Window
-
Window-of-Opportunity (Pre-surgery)
-
Refractory (Post-surgery)
-
Gynecomastia
A Global Effort
We work with organizations throughout the world to move our programs forward in an efficient and cost-effective manner.
A Global Effort
We work with organizations throughout the world to move our programs forward in an efficient and cost-effective manner.
